We also show a more significant association of SGLT-1i with a reduction in serum ALT rather than AST concentration, a pattern consistent with liver fat reduction.25 Given the emerging evidence of SGLT-2i in the treatment of NAFLD,7,8,25 clinical trials evaluating dual SGLT1/2 inhibitors are needed to investigate its therapeutic potential and preventative effects for NAFLD. Here, SLC5A1 is linked to metabolic dysfunction-associated steatotic liver disease.